When it comes to NVDA… “acceleration cycles” are the key

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Eliana Clark Biography and Net Worth

EVP of Intellia Therapeutics

Eliana Clark brings to Intellia nearly 20 years of experience in the biopharmaceutical industry. Prior to Intellia, Eliana spent seven years in many leadership roles at Biogen, including vice president of Product Development and Portfolio Management, vice president of International Manufacturing Operations and vice president of Global Manufacturing Sciences. In her most recent role, she led the team responsible for product strategy, supply and lifecycle management for their entire product portfolio. Before Biogen, Eliana spent many years at Sanofi/Genzyme, where she held leadership roles in formulation development, technical services and CMC regulatory. Prior to working in industry, Eliana was a professor at Tufts University in the Chemical and Biological Engineering Department for nearly 15 years.

As chief technical officer at Intellia, Eliana is responsible for building out our manufacturing capabilities and CMC to support the necessary requirements for clinical trials and global regulatory filings. She holds a B.A. and Ph.D. in Chemical Engineering from the Universidad Nacional de Litoral in Santa Fe, Argentina, and has graduated from the Greater Boston Executive Program at MIT Sloan School of Management.

What is Eliana Clark's net worth?: The estimated net worth of Eliana Clark is at least $937,686.40 as of July 1st, 2024. Ms. Clark owns 71,470 shares of Intellia Therapeutics stock worth more than $937,686 as of November 21st. This net worth approximation does not reflect any other assets that Ms. Clark may own. Learn More about Eliana Clark's net worth.
How do I contact Eliana Clark?: The corporate mailing address for Ms. Clark and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on Eliana Clark's contact information.
Has Eliana Clark been buying or selling shares of Intellia Therapeutics?: Eliana Clark has not been actively trading shares of Intellia Therapeutics during the last ninety days. Most recently, Eliana Clark sold 405 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $22.93, for a transaction totalling $9,286.65. Following the completion of the sale, the executive vice president now directly owns 71,470 shares of the company's stock, valued at $1,638,807.10. Learn More on Eliana Clark's trading history.
Who are Intellia Therapeutics' active insiders?: Intellia Therapeutics' insider roster includes Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?: In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company. Learn More about insider trades at Intellia Therapeutics.
Information on this page was last updated on 10/2/2024.

Eliana Clark Insider Trading History at Intellia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2024	Sell	405	$22.93	$9,286.65	71,470
7/3/2023	Sell	360	$40.51	$14,583.60	45,146
6/20/2023	Sell	5,000	$45.00	$225,000.00	45,146

Eliana Clark Buying and Selling Activity at Intellia Therapeutics

Intellia Therapeutics Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $13.12

$12.82

$14.27

50 Day Range

MA: $18.40

$13.97

$22.93

2 Week Range

Now: $13.12

$12.82

$34.87

Volume

4,471,151 shs

Average Volume

3,411,170 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81